2019 Next Generation Rx Forum Agenda

7:00 am REGISTRATION OPENS (Continental breakfast)
8:30 am - 8:45 am

Welcome and Opening Remarks

Mike Lonergan, President Drug Management Solutions
Pharmaceutical Strategies Group

Sharon Frazee, PhD, MPH, Sr Vice President of Research and Data Innovation
PBMI
8:45 am - 9:45 am

On the Brink of Change

Dr. Jan Berger, CEO
Health Intelligence Partners

Dr. Berger will open the meeting with an informative and insightful presentation on how the industry is “On the Brink of Change.” During this presentation, Dr. Berger will address what we know, what’s next, what we should be thinking about, and share predictions.

9:45 am - 10:45 am

Are you Ready for Next Generation Therapy?

Susan Trieu, PharmD, Director Enterprise Specialty Clinical Solutions
MedImpact Healthcare Systems

During this presentation, the speaker will discuss pipeline agents that will potentially revolutionize treatment in the near future.  As a payer, are you prepared to evaluate, budget and manage these innovative treatments? 

10:45 am - 11:30 am 

The Importance of a Value-Based PBM

Matthew Lee, Vice President of Strategic Partnerships
EmpiRx Health


During this session, the speaker will discuss new and relevant insights that will help transform the management of pharmacy benefits, specifically why your PBM should be considering a value-based model.

Major topics of discussion include:
  • When the world evolves, the PBM system must evolve with it
  • Evidence-based clinical care is important for your members and your bottom line
  • Putting the pharmacist at the center of pharmacy benefit management guarantees lower costs and improved outcomes
  • PBMs can only succeed when all stakeholders succeed
11:30 pm - 12:30 pm  LUNCH
12:30 pm - 1:30 pm 

How to Interpret and Manage New PBM Industry Changes, What is Going to Work and Why?

Jennifer Kingsley‑Wilson , CEO
ArmsRx


The speaker will review how new changes will affect plan sponsors, and also help the audience understand if a formulary without rebates is good for them. In addition, the speaker will review creative ways to beat the system with specialty pharmacy costs. During this session, the attendees will also gain insight into understanding the impact of pharmacogenetics under the medical and pharmacy benefit.
1:30 pm - 2:30 pm 

Using AI and Big DNA Data to Advance Drug Development and Delivery

Ian Jenkins, CEO
Frelii


Artificial intelligence is rapidly advancing the capabilities and possibilities of whole genome sequencing. Through the use of this advanced technology, the pharmaceutical industry can deliver precise dosing on a scale and at a level of accuracy never before seen. AI can provide personalized predictions to determine likely physical and psychological effects of drug interaction in an individual body. While big data is increasing our access to questions, it is also creating new discoveries and new questions that have yet to be answered. One thing is for sure, AI, big data and whole genome sequencing will impact the cost of drug development and delivery. This presentation will explore these topics in depth.
2:30 pm - 2:45 pm BREAK
2:45 pm - 3:30 pm 

Improving Health Outcomes for Members with Chronic Conditions: A Systematic "Turn Key" Approach Using MTM and Genetics to Improve Member Satisfaction and Lower Costs

Jeff Shaman, PhD, Chief Science Officer
Coriell Life Sciences


The speaker will share perspectives into the strategic reduction of healthcare costs by educating and engaging employees in a medication therapy management (MTM) program that incorporates genetics.  Attendees will learn how to strategically and efficiently evaluate and incorporate genetic technology into existing pharmaceutical appropriateness, wellness, and customer engagement programs.
3:30 pm - 4:30 pm 

Proactive Fraud Waste & Abuse Detection with Data Science & Machine Learning

Renee Rayburg, RPh, Vice President of Specialty Clinical Consulting
Artemetrx
Jeremy Weidner, Associate Data Scientist
Pharmaceutical Strategies Group


Fraud Waste & Abuse (FWA) accounts for approximately 1% of prescription drug spending – costing plan sponsors hundreds of millions of dollars every year. Yet detecting the next fraudulent scheme can be challenging as these schemes can involve drugs such as topical creams and high cost generics which currently fly under the radar of most payers and PBMs. In the session PSG’s VP of Specialty Clinical Consulting, Renee Rayburg, and Associate Data Scientist, Jeremy Weidner, will present a real-world example of how machine learning and advanced analytics were leveraged to root out potential FWA before it became a million-dollar problem for a plan sponsor. They will share specific strategies as to how plan sponsors can proactively identify and address FWA to avoid unnecessary prescription drug cost and minimize member disruption. 
4:30 pm - 4:45 pm 

Closing Remarks 

Sharon Frazee, PhD, MPH, Sr Vice President of Research and Data Innovation
PBMI
  Subject to change